Preliminary clinical results with norgamem (thioproline) and revercan (2-amino-2-thiazoline): the first inducers of reverse transformation.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013844:Thiazoles / Q000627:therapeutic use*; D053778:Thiazolidines; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D013844:Thiazoles; D053778:Thiazolidines; C031363:2-aminothiazoline; C003438:thiazolidine-4-carboxylic acid